The SUPPRELIN® LA Support Center

We’ll be with you every step of the way

Because healthcare plans, insurance options, copays, and the process of reimbursement can be complex, we’ll be with you every step of the way.

The SUPPRELIN® LA Support Center offers you assistance as your child begins treatment by verifying benefits, confirming copay or payment responsibilities (if any), to ensure your child’s medicine is shipped.

Support Center Contact Info

Your Support Center representative will work to help you understand your benefits by:

  • Assisting with verification of insurance coverage
  • Clarifying deductibles and copay for treatment and procedures
  • Providing information to eligible families about the SHARES Program, a financial support program
  • Answering general reimbursement questions
  • Coordinating the shipment of SUPPRELIN® LA directly to the procedure center identified by your child’s healthcare professional

Getting started with SUPPRELIN® LA

Submitting the Form
Your healthcare provider may submit a Service Request Enrollment Form to the SUPPRELIN® LA Support Center to verify insurance coverage, benefits, and any next steps, such as prior authorization or product access options.

Communications
A staff member from the SUPPRELIN® LA Support Center will provide you and your physician with information about your insurance coverage and other access or assistance details that may assist you in understanding the treatment journey.

Continued Support
About 11 months after researching your insurance coverage, the SUPPRELIN® LA Support Center will remind your child’s doctor that it’s time to evaluate your child's central precocious puberty (CPP) treatment plan and will repeat the insurance verification as instructed by the physician.

 
See More
IMPORTANT SAFETY
INFORMATION ABOUT SUPPRELIN® LA
  • SUPPRELIN® LA should not be taken if your child is allergic to gonadotropin releasing hormone (GnRH), GnRH agonist medicines, or any ingredients in the SUPPRELIN® LA implant, or is pregnant or becomes pregnant. SUPPRELIN® LA can cause birth defects or loss of the baby. If your child becomes pregnant, call your doctor.

  • In the first week of treatment, SUPPRELIN® LA can cause an increase in some hormones. During this time, you may notice more signs of puberty in your child, including light vaginal bleeding and breast enlargement in girls. Within 4 weeks of treatment, you should see signs in your child that puberty is stopping.

  • Some people have had implant breakage during the removal process.

  • Some people who had SUPPRELIN® LA placed in their arm have had the implant come through the skin (extrusion). Call your child's doctor right away if the SUPPRELIN® LA implant comes through the skin.

  • Some people taking GnRH agonists like SUPPRELIN® LA have had new or worsening mental (psychiatric) problems including depression. Mental (psychiatric) problems may include emotional symptoms such as crying, irritability, restlessness (impatience), anger, and acting aggressive. Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of mental problems. Call your child's doctor right away if your child has any new or worsening mental symptoms or problems while taking SUPPRELIN® LA.

  • Some people taking GnRH agonists like SUPPRELIN® LA have had seizures. The risk of seizures may be higher in people who have a history of seizures, epilepsy, brain or brain vessel (cerebrovascular) problems or tumors, or who are taking a medicine that has been connected to seizures such as bupropion or selective serotonin reuptake inhibitors (SSRIs). Seizures have also happened in people who have not had any of these problems. Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of these problems, as well as all the medicines they take. Call your child's doctor right away if your child has a seizure while taking SUPPRELIN® LA.

  • Increased pressure in the fluid around the brain can happen in children taking GnRH agonist medicines, including SUPPRELIN® LA. Call your child's doctor right away if your child has any of the following symptoms during treatment with SUPPRELIN® LA: headache, eye problems, including blurred vision, double vision, and decreased eyesight, eye pain, ringing in the ears, dizziness, nausea.

  • Your child's doctor should do tests to make sure your child has CPP before treating with SUPPRELIN® LA. SUPPRELIN® LA lasts for 12 months. One implant will give the medicine for 12 months. After 12 months, SUPPRELIN® LA must be removed. The doctor may insert a new SUPPRELIN® LA at this time to continue treatment.

  • SUPPRELIN® LA is placed under the skin of the inside of the upper arm. The doctor will numb the arm of your child, make a small cut, and then place SUPPRELIN® LA under the skin. The cut may be closed with stitches or surgical strips and covered with a pressure bandage.

  • Your child should keep the arm clean and dry and should not swim or bathe for 24 hours after receiving the SUPPRELIN® LA implant. The bandage can be removed after 24 hours. Do not remove any surgical strips. They will fall off on their own in a few days. Your child should avoid heavy play or exercise that uses the implanted arm for 7 days. You and your child should routinely check the insertion site until the cut is healed. After the cut has healed, your child can go back to his or her normal activities. The doctor will give you complete instructions.

  • Keep all scheduled visits to the doctor. Your child's doctor will do regular exams and blood tests to check for signs of puberty. Sometimes the doctor will have to do special tests, such as ultrasound or MRI, if the SUPPRELIN® LA implant is difficult to find under your child's skin.

  • The most common side effects of SUPPRELIN® LA are skin reactions at the place where the implant is inserted. These reactions may include pain, redness, bruising, soreness, and swelling in and around the implant site. Call your child's doctor if your child has bleeding, redness, or severe pain where the implant was inserted.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

WHAT IS SUPPRELIN® LA?
  • SUPPRELIN® LA is an implanted gonadotropin releasing hormone (GnRH) medicine used for the treatment of children with central precocious puberty (CPP).

  • It is not known if SUPPRELIN® LA is safe and effective in children under 2 years of age.

Please see the full Prescribing Information, including Medication Guide.

See More
IMPORTANT SAFETY
INFORMATION ABOUT SUPPRELIN® LA
  • SUPPRELIN® LA should not be taken if your child is allergic to gonadotropin releasing hormone (GnRH), GnRH agonist medicines, or any ingredients in the SUPPRELIN® LA implant, or is pregnant or becomes pregnant. SUPPRELIN® LA can cause birth defects or loss of the baby. If your child becomes pregnant, call your doctor.

  • In the first week of treatment, SUPPRELIN® LA can cause an increase in some hormones. During this time, you may notice more signs of puberty in your child, including light vaginal bleeding and breast enlargement in girls. Within 4 weeks of treatment, you should see signs in your child that puberty is stopping.

  • Some people have had implant breakage during the removal process.

  • Some people who had SUPPRELIN® LA placed in their arm have had the implant come through the skin (extrusion). Call your child's doctor right away if the SUPPRELIN® LA implant comes through the skin.

  • Some people taking GnRH agonists like SUPPRELIN® LA have had new or worsening mental (psychiatric) problems including depression. Mental (psychiatric) problems may include emotional symptoms such as crying, irritability, restlessness (impatience), anger, and acting aggressive. Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of mental problems. Call your child's doctor right away if your child has any new or worsening mental symptoms or problems while taking SUPPRELIN® LA.

  • Some people taking GnRH agonists like SUPPRELIN® LA have had seizures. The risk of seizures may be higher in people who have a history of seizures, epilepsy, brain or brain vessel (cerebrovascular) problems or tumors, or who are taking a medicine that has been connected to seizures such as bupropion or selective serotonin reuptake inhibitors (SSRIs). Seizures have also happened in people who have not had any of these problems. Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of these problems, as well as all the medicines they take. Call your child's doctor right away if your child has a seizure while taking SUPPRELIN® LA.

  • Increased pressure in the fluid around the brain can happen in children taking GnRH agonist medicines, including SUPPRELIN® LA. Call your child's doctor right away if your child has any of the following symptoms during treatment with SUPPRELIN® LA: headache, eye problems, including blurred vision, double vision, and decreased eyesight, eye pain, ringing in the ears, dizziness, nausea.

  • Your child's doctor should do tests to make sure your child has CPP before treating with SUPPRELIN® LA. SUPPRELIN® LA lasts for 12 months. One implant will give the medicine for 12 months. After 12 months, SUPPRELIN® LA must be removed. The doctor may insert a new SUPPRELIN® LA at this time to continue treatment.

  • SUPPRELIN® LA is placed under the skin of the inside of the upper arm. The doctor will numb the arm of your child, make a small cut, and then place SUPPRELIN® LA under the skin. The cut may be closed with stitches or surgical strips and covered with a pressure bandage.

  • Your child should keep the arm clean and dry and should not swim or bathe for 24 hours after receiving the SUPPRELIN® LA implant. The bandage can be removed after 24 hours. Do not remove any surgical strips. They will fall off on their own in a few days. Your child should avoid heavy play or exercise that uses the implanted arm for 7 days. You and your child should routinely check the insertion site until the cut is healed. After the cut has healed, your child can go back to his or her normal activities. The doctor will give you complete instructions.

  • Keep all scheduled visits to the doctor. Your child's doctor will do regular exams and blood tests to check for signs of puberty. Sometimes the doctor will have to do special tests, such as ultrasound or MRI, if the SUPPRELIN® LA implant is difficult to find under your child's skin.

  • The most common side effects of SUPPRELIN® LA are skin reactions at the place where the implant is inserted. These reactions may include pain, redness, bruising, soreness, and swelling in and around the implant site. Call your child's doctor if your child has bleeding, redness, or severe pain where the implant was inserted.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

WHAT IS SUPPRELIN® LA?
  • SUPPRELIN® LA is an implanted gonadotropin releasing hormone (GnRH) medicine used for the treatment of children with central precocious puberty (CPP).

  • It is not known if SUPPRELIN® LA is safe and effective in children under 2 years of age.

Please see the full Prescribing Information, including Medication Guide.

References: 1. SUPPRELIN® LA [package insert]. Endo Pharmaceuticals Inc. 2. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697-1704. 3. Silverman LA, Neely EK, Kletter GB, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab. 2015;100(6):2354-2363. 4. Data on file. DOF-SP-27. Endo Pharmaceuticals Inc.; August 2020.

HEALTHCARE PROFESSIONALS

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click continue if you are a healthcare professional.

You are now leaving the SUPPRELIN® LA website.
Endo is not responsible for the content of linked sites.